Indications 

Prolopa CR is a prescription medication used in the treatment of Parkinson’s disease, helping to relieve symptoms such as tremors, stiffness, and difficulty with movement. It contains a combination of levodopa and benserazide.  

Levodopa is converted into dopamine in the brain, which is a neurotransmitter that helps regulate movement. Benserazide is added to levodopa to prevent its breakdown before it reaches the brain, allowing for more effective conversion to dopamine. 

Prolopa CR is an extended-release formulation, which means that the medication is released slowly over time, providing a more continuous and sustained effect compared to regular Prolopa. This can help with reducing “off” periods and improving symptom control. 

Use and Dosage 

Prolopa CR should be taken as prescribed by your healthcare provider. It is usually taken orally, with or without food. Swallow the Prolopa CR capsule whole with a glass of water. Do not crush, chew, or break the capsule, as it is designed for extended release. It can be taken with or without food. However, taking it with a high-protein meal can reduce its absorption, take it at least 30 minutes before or 60 minutes after meals. 

Abrupt discontinuation of levodopa therapy may lead to withdrawal syndrome, characterized by symptoms such as fever, muscular rigidity, and altered consciousness. Dose reduction should be done under medical supervision. 

If you miss a dose, take it as soon as you remember. However, if it is close to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. 

Side Effects 

Common Side Effects 

• Agitation 
• Anxiety 
• Blurred vision 
• Confusion 
• Dizziness 
• Drowsiness 
• Dry mouth 
• Headache 
• Insomnia 
• Loss of appetite 
• Muscle cramps 
• Nausea 
• Skin rash 
• Sweating 
• Urinary retention 
• Vomiting 

Serious Side Effects 

• Hallucinations 
• Psychosis 
• Compulsive behaviors (such as gambling, shopping, and sex) 
• Orthostatic hypotension (drop in blood pressure upon standing) 
• Dyskinesia (involuntary movements) 
• Worsening of Parkinson’s disease symptoms (when medication wears off) 
• Neuroleptic malignant syndrome (rare but potentially life-threatening reaction) 

Cautions 

• Narrow-angle glaucoma: Levodopa should be used with caution in individuals with narrow-angle glaucoma, as it may increase intraocular pressure. 
• Psychiatric disorders: Levodopa can cause or worsen psychiatric symptoms such as hallucinations, confusion, agitation, and delusions. It should be used cautiously in patients with a history of psychiatric disorders. 
• Cardiovascular disease: Levodopa may cause or exacerbate cardiovascular symptoms such as irregular heartbeat, low blood pressure, or changes in heart rhythm. Patients with pre-existing cardiovascular conditions should be closely monitored. 
• Renal impairment: Levodopa is primarily excreted by the kidneys, so caution should be exercised in patients with renal impairment. Dose adjustments may be necessary. 
• Hepatic impairment: Levodopa is metabolized in the liver, so patients with hepatic impairment may require dose adjustments and close monitoring. 
• Peptic ulcer disease: Levodopa can increase the risk of gastrointestinal bleeding in patients with peptic ulcer disease. Close monitoring and appropriate management are necessary. 
• History of melanoma: There have been reports of an increased risk of melanoma in patients with Parkinson’s disease and a history of levodopa use. Patients with a history of melanoma should be monitored for skin changes and receive regular dermatological evaluations. 
• Dyskinesias: Levodopa therapy may lead to the development or worsening of involuntary movements known as dyskinesias. Patients should be monitored for the onset or exacerbation of these symptoms. 
• Endocrine disorders: Levodopa may interfere with certain laboratory tests for catecholamines and can cause false-positive results. Inform healthcare providers about levodopa therapy before undergoing such tests. 
• History of melanoma or suspicious skin lesions: Patients with a history of melanoma or suspicious skin lesions should be carefully monitored while taking levodopa due to the potential risk of melanoma development or growth. 
• Drug addiction: Patients with a history of drug addiction or substance abuse should be closely monitored for potential misuse or dependence on levodopa.